Effect of BCRP wild-type on cytotoxity induced by mitoxantrone, calicheamicin-g1, and GO
A 58-year-old man was initially diagnosed with HCL in May 2001 and treated with 2-CdA, which resulted in a complete remission that lasted for one and a half years. He then presented at MD Anderson Cancer Center. His initial diagnostic material was not available to us, but his BM biopsy performed at our institution 2 years after diagnosis showed relapse of disease with 70% of leukemic infiltrate in an 80% cellular marrow. Smears showed that 57% of nucleated BM cells were hairy cells, of which 60% were unusually large (Figure 1d ). Flow cytometry demonstrated an immunophenotype consistent with HCL (CD19 þ , CD25 þ , CD11c þ , and CD103 þ ). At the time this report was written, he was receiving Rituximab.
Discussion
We presented three cases of HCL with large hairy cells. The percentage of large cells appeared to increase over time during the disease course. However, the significance of the presence of large hairy cells is not clear. Transformation of HCL to EpsteinBarr virus (EBV)-positive aggressive B-cell lymphoma has been reported, 4 but the lymphoma might have been a clonally independent disease. We performed in situ hybridization on the three cases and in none of them were the hairy cells positive for EBV-encoded small RNA. Recent karyotyping on the three cases showed del(1)(p31p12), inv(6)(p21.1p23), and diploidy, respectively. It is not clear whether the abnormal karyotype in the two cases resulted from progression or was present at the early stages. The presence of large cells may not be necessarily an indication that the disease has become more aggressive. As seen in our cases, a good response to conventional HCL therapies can still be achieved even with high percentage of large hairy cells. Gemtuzumab ozogamicin (GO, Mylotargt), a novel immunoconjugate therapy for acute myeloid leukemia (AML), consists of a humanized anti-CD33 antibody conjugated to a calicheamicin-g1 derivative, N-acetyl gamma calicheamicin dimethyl hydrazine. After internalization, the cytotoxic moiety is released and activated to a highly reactive species that ultimately causes cell death. 1 GO alone induces remissions in approximately 30% of adults with CD33 þ , relapsed AML. 2 The mechanisms underlying GO resistance are incompletely understood; however, efflux of the calicheamicin moiety by P-glycoprotein (Pgp) and, to a lesser extent, multidrug resistance protein (MRP), has been implicated. 3 Breast cancer resistance protein (BCRP/ABCG2), another member of the adenosine triphosphate-binding cassette (ABC) family of transporters, is widely expressed in normal tissues, including primitive hematopoietic stem cells. Evidence to date suggests that BCRP mainly serves to protect cells from xenobiotic toxins, although additional functions in stem cell populations are discussed. 4, 5 BCRP confers resistance to certain chemotherapeutic agents; however, the substrate specificity in cells containing a mutation at codon 482 (R482T or R482G) differs somewhat from cells expressing wild-type protein. 4, 5 BCRP mRNA and protein are variably expressed in AML. 5, 6 So far, only wild-type BCRP (ie arginine at codon 482) has been found in primary AML samples 7 (and A Suvannasankha et al. Blood 2002; 100: 67a; abstract), whereas R482T and R482G variants have been identified in drug-selected cell lines. 4, 5 It remains unknown whether mutations at codon 482 might occur in patients after treatment with BCRP substrate drugs. The significance of BCRP for clinical outcome in AML is presently unclear. Some studies, but not others, have correlated BCRP gene expression with a worse response to conventional chemotherapy. 5, 6 Only infrequent leukemic subpopulations appear to express BCRP mRNA at levels equivalent to those of drug-resistant cell lines, but high BCRP transcript levels have been noted in immature, CD34
þ AML blasts 5, 6 (and MHGP Raaijmakers et al. Blood 2002; 100: 138a; abstract).
Given that BCRP-mediated drug resistance profile partially overlaps those associated with Pgp or MRP, and that additional unidentified mechanisms likely play a role in resistance to GO, 3, 8 we investigated whether BCRP (wild type or R482T) could confer resistance to GO or to the unconjugated calicheamicin-g1 derivative. For this purpose, lentiviral pRRLsin.cPPT.MSCV.BCRP-IRES-EGFP vectors were generated by cloning BCRP cDNA (wild type or R482T; provided by DD Ross, University of Maryland, Baltimore, MD, USA) into pRRLsin.cPPT.MSCV as a BCRP-IRES-EGFP cassette. The products of both inserts were verified by sequencing. The vector pRRLsin.cPPT.MSCV.GFP was used as control. Drug-sensitive human AML cell lines were transduced at a multiplicity of infection (MOI) of 10-100, and EGFP-positive cells were sorted by flow cytometry and recultured for further analysis.
Parental CD33 þ ML-1, NB4, U937, and HL-60 cells displayed either no or only minimal BCRP protein, as measured by immunofluorescence with anti-BCRP antibody (clone BXP-34; 4, 5 Figure 1) . Similarly, no BCRP activity could be detected by mitoxantrone efflux in the presence or absence of the fumitremorgin C analog Ko143 (provided by AH Schinkel, The Netherlands Cancer Institute, Amsterdam, The Netherlands), which is a sensitive, specific, and nontoxic inhibitor of BCRP 5 ( Figure 1 ). In comparison, lentivirus-mediated transduction of wild-type or R482T BCRP at an MOI of up to 100 yielded stable subpopulations of cells with significant BCRP protein expression and activity (Figure 1) .
For the assessment of drug sensitivities, cells were incubated in medium containing GO, N-acetyl gamma calicheamicin dimethyl hydrazine (referred to as calicheamicin-g1; both provided by Wyeth-Ayerst Research, Radnor, PA, USA), or mitoxantrone in the presence of either Ko143 at the predetermined optimal concentration for the individual cell line (200 or 600 nM) or vehicle (DMSO). In experiments using calicheamicin-g1 or mitoxantrone, cells were continuously exposed to both the cytotoxic drug and Ko143 or vehicle. In experiments with GO, cells were washed after 2 h and resuspended in medium containing Ko143 or vehicle to mimic in vivo pharmacokinetics of GO and to minimize CD33-independent uptake. After 3 days, cell numbers and drug-induced cytotoxicity, using propidium iodide (PI) to detect non-viable cells, were determined by flow cytometry. Parental and empty-vectortransduced cell lines were highly susceptible to cytotoxicity induced by mitoxantrone, calicheamicin-g1, or GO. As expected, 4,5 cells overexpressing either wild-type or R482T BCRP were resistant to mitoxantrone, and coincubation with Ko143 restored sensitivity (Tables 1 and 2 ). In contrast, overexpression of either wild-type or R482T BCRP did not alter GO-or calicheamicin-g1-induced cytotoxicities, and Ko143 had no effect on drug susceptibilities (Tables 1 and 2 ; note that R482T-transduced HL-60 cells were not established). These results were verified by cell count determinations (data not shown). Together, our findings indicate that BCRP does not confer resistance to either GO or calicheamicin-g1 in human CD33
þ leukemic cell lines. They further suggest that calicheamicin-g1 is not a substrate for either wild-type or R482T BCRP.
Our result that calicheamicin-g1 is not a substrate for BCRP is reassuring for the clinical application of GO in AML and for other experimental calicheamicin-g1-based therapies. Alternatively, the growing evidence that BCRP is expressed in normal primitive cell populations and many adult tissues 4, 5 raises the caution that inadvertent delivery of calicheamicin-g1, either via nonreceptor-mediated uptake of GO or via uptake of free calicheamicin-g1, might lead to increased toxicity if the normal tissue depends heavily on the cytoprotective function of BCRP. 
